The 25-Hydroxy Vitamin D test runs on Roche's Cobas I 601 analyzer and is the first in Roche's pipeline for the Cobas Mass Spec solution.

Against the backdrop of a reverse stock split to get back in compliance with Nasdaq's listing requirements, the firm said that it remains on solid operational footing.

The company plans to raise money this fall to support the continued development of its head-and-neck cancer testing platform and oral squamous cell carcinoma test.

The firm said that the reverse split is intended to help the company to regain compliance with the Nasdaq's $1.00 per share minimum bid price requirement.

The company's clinical chemistry test uses the NGAL biomarker to determine a patient's risk of acute kidney injury.

Proscia has integrated its Concentriq platform with AWS HealthImaging to provide a cloud-native foundation for pathology.

The submitted test runs on the firm's point-of-care instrument and detects four respiratory pathogens within 10 minutes directly from patient nasal swab samples.

The program is intended to advance the development of antigen tests that can be used in homes and at the point-of-care to aid the detection of dangerous infections.

Under the agreement, Tempus and Renalytix will work with US healthcare systems to make the KidneyintelX.dkd test more available to order within existing clinical workflows.

Last week, readers were most interested in a story about a possible sale of Siemens Healthineer's IVD business, leading to an uptick in the company's share price.